Ibandronate Sodium (CAS 138844-81-2) Suppliers and Product Information

Ibandronate sodium is a nitrogen-containing bisphosphonate used for the treatment and prevention of osteoporosis in postmenopausal women. It inhibits osteoclast-mediated bone resorption and has been investigated for its potential anti-tumor effects.

Frequently Asked Questions about Ibandronate Sodium

Q: What is the mechanism of action of Ibandronate sodium?

A: Ibandronate sodium inhibits farnesyl diphosphate synthase (IC50 = 20 nM) and acts as a bone resorption inhibitor. Its mechanism of action is similar to other bisphosphonate agents.

Q: How is Ibandronate sodium administered?

A: Ibandronate sodium is available in oral tablet form for daily (2.5 mg) or monthly (150 mg) administration. It is also available in injectable formulations.

Q: What are the clinical effects of Ibandronate sodium?

A: When administered daily (2.5 mg), Ibandronate has been shown to reduce the risk of vertebral fractures by 62%. It has also been shown to increase bone mineral density (BMD) in the hip, femoral neck, and lumbar spine.

Q: Are there any special considerations for taking Ibandronate sodium?

A: The oral bioavailability of Ibandronate sodium is very low (0.6%) and is affected by food, beverages other than water, and other medications. It should not be taken with mineral water or calcium/vitamin D supplements. Patients with severe renal impairment (creatinine clearance < 30 mL/min) should not be prescribed Ibandronate sodium.